Please assess the completion status of the following clinical trial:

Trial Title: Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Girls ages 13 to 17~* Tanner IV or V stage of puberty~* Post-menarche~* Hyperandrogenemic (total testosterone \> 0.4 ng/mL or free testosterone \> 35 pmol/L) with or without hirsutism~* Normal aspartate aminotransferase/alanine aminotransferase (AST/ALT) (AST \< 35 U/L, ALT \< 55 U/L)~* Hemoglobin \> 12 mg/dL or Hematocrit \> 36%~* Normal screening labs (with exception of the expected hormonal abnormalities inherent in hyperandrogenemia)~* Sexually active subjects must agree to abstain or use double barrier contraception during the study~* Subjects must agree not to take any other medications during the course of the study without approval by the study investigators~Exclusion Criteria:~* Abnormal screening labs (with the exception of the expected hormonal abnormalities inherent in hyperandrogenemia)~* Elevated AST/ALT (AST \> 35 U/L, ALT \> 55 U/L)~* Hemoglobin \<12 mg/dL or hematocrit \< 36%~* Weight \< 32 kg~* History of liver disease, peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer~* Pregnant or breastfeeding~* On medications known to affect the reproductive axis within 3 months of the study (including oral contraceptive pills, metformin, and spironolactone)~* On medications known or likely to inhibit or induce CYP1A2 or CYP3A4 (please see Restrictions on use of other drugs or treatments section below for common examples of such drugs)~* Are currently participating in another study or have been in one in the last 30 days.

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Flutamide, estrace, progesterone (Type: EXPERIMENTAL): For flutamide, subjects weighing \> 50 kg will receive 250 mg orally twice a day, and subjects weighing \< 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission.

Based on this trial design, predict the completion outcome and termination type (if applicable).